|
A Study of IC351 (tadalafil) for the treatment of diabetic patients with symptoms of dyspepsia (upset stomach) and gastroparesis (delayed gastric emptying). Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on A Study of IC351 (tadalafil) for the treatment of diabetic patients with symptoms of dyspepsia (upset stomach) and gastroparesis (delayed gastric emptying). conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A Study of IC351 (tadalafil) for the treatment of diabetic patients with symptoms of dyspepsia (upset stomach) and gastroparesis (delayed gastric emptying). Clinical research trials and A Study of IC351 (tadalafil) for the treatment of diabetic patients with symptoms of dyspepsia (upset stomach) and gastroparesis (delayed gastric emptying). healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like A Study of IC351 (tadalafil) for the treatment of diabetic patients with symptoms of dyspepsia (upset stomach) and gastroparesis (delayed gastric emptying).. A Study of IC351 (tadalafil) for the treatment of diabetic patients with symptoms of dyspepsia (upset stomach) and gastroparesis (delayed gastric emptying). Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a A Study of IC351 (tadalafil) for the treatment of diabetic patients with symptoms of dyspepsia (upset stomach) and gastroparesis (delayed gastric emptying). clinical trial. Human subjects often obtain the finest healthcare possible for their A Study of IC351 (tadalafil) for the treatment of diabetic patients with symptoms of dyspepsia (upset stomach) and gastroparesis (delayed gastric emptying). condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of IC351 (tadalafil) for the treatment of diabetic patients with symptoms of dyspepsia (upset stomach) and gastroparesis (delayed gastric emptying).  A Study of IC351 (tadalafil) for the treatment of diabetic patients with symptoms of dyspepsia (upset stomach) and gastroparesis (delayed gastric emptying).
A Study of IC351 (tadalafil) for the treatment of diabetic patients with symptoms of dyspepsia (upset stomach) and gastroparesis (delayed gastric emptying).
For Condition: Gastroparesis
Status: Terminated
Sponsor(s): Eli Lilly and Company ,
Synopsis: The purposes of this study are to determine whether an experimental drug known as IC351 (tadalafil) can reduce symptoms of dyspepsia in diabetic patients (fullness after eating, inability to finish a regular meal, bloating, discomfort or pain in the upper abdomen, belching after meals, nausea, vomiting), and/or reduce the amount of time the stomach takes to empty the contents of a standard meal. The safety of IC351 given once daily for 8 weeks in this population will also be studied.
Details:
Eligibility:
Study Type: Interventional, Treatment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/69 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Diagnosis of diabetes mellitus - Delayed gastric emptying - History of upper abdominal discomfort - Symptoms of dyspepsia (upset stomach) Exclusion Criteria: - Major gastrointestinal surgery or medical conditions known to affect gastric motility - Irritable Bowl Syndrome - Medications known to affect gastric motility - Angina treated with nitrates - Uncontrolled diabetes mellitus
Total Enrollment:
Location and Contact Information:
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician".
Vancouver, British Columbia,
Canada
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician".
Saskatoon, Saskatchewan,
Canada
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician".
Hamilton, Ontario,
Canada
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician".
Sainte-Foy, Quebec,
Canada
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician".
Victoria, British Columbia,
Canada
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician".
Courtice, Ontario,
Canada
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician".
Ottawa, Ontario,
Canada
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician".
Edmonton, Alberta,
Canada
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician".
Montreal, Quebec,
Canada
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician".
Kitchener, Ontario,
Canada
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician".
Winnipeg, Manitoba,
Canada
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician".
London, Ontario,
Canada
Additional Information:
Study ID Numbers: 4979;
Study Start Date: February 2003
Record last reviewed: June 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00050609
Other Gastroparesis Studies:
1. A Study of IC351 (tadalafil) for the treatment of diabetic patients with symptoms of dyspepsia (upset stomach) and gastroparesis (delayed gastric emptying).
2. Safety and effectiveness of an investigational agent (GM-611) in patients with diabetic gastroparesis
Related Studies:
Other Gastroparesis Clinical Trials
Other Ontario Clinical Trials
Other Ottawa Clinical Trials
A Study of IC351 (tadalafil) for the treatment of diabetic patients with symptoms of dyspepsia (upset stomach) and gastroparesis (delayed gastric emptying).
|
|
|
|
|
|
|
|
